

FULL TEXT LINKS



Comparative Study > *Pharmacol Res.* 2020 Sep;159:104940.

doi: 10.1016/j.phrs.2020.104940. Epub 2020 May 26.

## Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB<sub>1</sub>, CB<sub>2</sub> and CB<sub>1</sub>/CB<sub>2</sub> heteromer receptors

Gemma Navarro<sup>1</sup>, Katia Varani<sup>2</sup>, Alejandro Lillo<sup>3</sup>, Fabrizio Vincenzi<sup>2</sup>, Rafael Rivas-Santisteban<sup>4</sup>, Iu Raich<sup>4</sup>, Irene Reyes-Resina<sup>4</sup>, Carlos Ferreiro-Vera<sup>5</sup>, Pier Andrea Borea<sup>6</sup>, Verónica Sánchez de Medina<sup>5</sup>, Xavier Nadal<sup>7</sup>, Rafael Franco<sup>8</sup>

Affiliations

PMID: 32470563 DOI: [10.1016/j.phrs.2020.104940](https://doi.org/10.1016/j.phrs.2020.104940)

### Abstract

**Background:** Recent approved medicines whose active principles are  $\Delta^9$ Tetrahydrocannabinol ( $\Delta^9$ -THC) and/or cannabidiol (CBD) open novel perspectives for other phytocannabinoids also present in *Cannabis sativa* L. varieties. Furthermore, solid data on the potential benefits of acidic and varinic phytocannabinoids in a variety of diseases are already available. Mode of action of cannabigerol (CBG), cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), cannabidivarin (CBDV) and cannabigerivarin (CBGV) is, to the very least, partial.

**Hypothesis/purpose:** Cannabinoid CB<sub>1</sub> or CB<sub>2</sub> receptors, which belong to the G-protein-coupled receptor (GPCR) family, are important mediators of the action of those cannabinoids. Pure CBG, CBDA, CBGA, CBDV and CBGV from *Cannabis sativa* L. are differentially acting on CB<sub>1</sub> or CB<sub>2</sub> cannabinoid receptors.

**Study design:** Determination of the affinity of phytocannabinoids for cannabinoid receptors and functional assessment of effects promoted by these compounds when interacting with cannabinoid receptors.

**Methods:** A heterologous system expressing the human versions of CB<sub>1</sub> and/or CB<sub>2</sub> receptors was used. Binding to membranes was measured using radioligands and binding to living cells using a homogenous time resolved fluorescence resonance energy transfer (HTRF) assay. Four different functional outputs were assayed: determination of cAMP levels and of extracellular-signal-related-kinase phosphorylation, label-free dynamic mass redistribution (DMR) and  $\beta$ -arrestin recruitment.

**Results:** Affinity of cannabinoids depend on the ligand of reference and may be different in membranes and in living cells. All tested phytocannabinoids have agonist-like behavior but behaved as inverse-agonists in the presence of selective receptor agonists. CBGV displayed enhanced potency in many of the functional outputs. However, the most interesting result was a biased signaling that correlated with differential affinity, i.e. the overall results suggest that the binding mode of each ligand leads to specific receptor conformations underlying biased signaling outputs.

**Conclusion:** Results here reported and the recent elucidation of the three-dimensional structure of CB<sub>1</sub> and CB<sub>2</sub> receptors help understanding the mechanism of action that might be protective and the molecular drug-receptor interactions underlying biased signaling.

**Keywords:** Biased signaling; Cytocin; GPCR structure; Homogeneous binding; Phytocannabinoids; Radioligand binding.

Copyright © 2020 Elsevier Ltd. All rights reserved.

## Related information

[MedGen](#)

[PubChem Compound \(MeSH Keyword\)](#)

## LinkOut - more resources

### Full Text Sources

[Elsevier Science](#)

[Ovid Technologies, Inc.](#)

### Research Materials

[NCI CPTC Antibody Characterization Program](#)

### Miscellaneous

[NCI CPTAC Assay Portal](#)